Chronic hepatitis C virus infection in children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 50, Issue 2, 2010, Pages 123-131

  Mohan, Neelam ^a   González Peralta, Regino P ^b   Fujisawa, Tomoo ^c   Chang, Mei Hwei ^d   Heller, Solange ^e   Jara, Paloma ^f   Kelly, Deirdre ^g   Mieli Vergani, Giorgina ^h   Shah, Uzma ⁱ   Murray, Karen F ^j  

^a SIR GANGA RAM HOSPITAL   (India)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Eastern Yokohama Hospital   (Japan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j Hepatobiliary Program   (United States)

more..

Author keywords

Chronic hepatitis C; Hepatitis; Hepatitis C virus; Pediatrics; Viral infection

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN;

ANEMIA; ANOREXIA; CHILD; CHILDHOOD DISEASE; CHRONIC HEPATITIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; CHILD; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL;

HEPATITIS C VIRUS;

EID: 76349115385     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181c61995     Document Type: Review

References (92)

1. Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development of hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 1998;143:2493-2503
2. Sy T, Jamal MM. Epidemiology of hepatitis C viral infection. Int J Med Sci 2006;3:41-46
3. Davison SM, Mieli-Vergani G, Kelly DA. Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child 2006;91:781-785
4. Shiraki K, Ohto H, Inaba N, et al. Guidelines for care of and guidance for pregnant women carrying hepatitis C virus and their infants. Pediatr Int 2008;50:138-140
5. Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000;31:751-755
6. Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis c virus in a chohort of 2,447 HIV-seronegative pregnant women: a 24 month prospective study. J Pediatr Gastroenterol Nutr 2001;33:570-575
7. Tovo PA, Palomba E, Ferraris G, et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV infection in children. Clin Infect Dis 1997;25:1121-1124
8. Della Bella S, Riva A, Tanzi E, et al. Hepatitis C virus-specific reactivity of CD4+-lymphocytes in children born from HCV-infected women. J Hepatol 2005;43:394-402.
9. Bosi I, Ancora G, Mantovani W, et al. HLA DR13 and HCV vertical infection. Pediatr Res 2002;51:746-749
10. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to woman seronegative for HIV-1. Br Med J 1998;317:437-441
11. Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000;356:904-907
12. Maccabruni A, Bossi G, Caselli D, et al. High efficiency of vertical transmission of hepatitis C virus among babies born to human immunodeficiency virus-negative women. Pediatr Infect Dis J 1995; 14:921-922
13. Ruiz-Extremera A, Salmeron J, Torres C, et al. Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. Pediatr Infect Dis J 2000;19:511-516
14. Inui A, Fujisawa T, Sogo T, et al. Different outcomes of vertical transmission of hepatitis C virus in a twin pregnancy. J Gastroenterol Hepatol 2002;17:617-619
15. Bortolotti F, Verucchi G, Cammà C, et al. Long term course of chronic hepatitis C in children: from viral clearance to end stage liver disease. Gastroenterology 2008;134:1900-1907
16. Yeung LT, To T, King SM, et al. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepatol 2007;14:797-805.
17. Tovo P-A, Pembrey LJ, Newell M-L. Persistence rate and progression of vertically acquired hepatitis C infection. J Infect Dis 2000;181:419-424
18. Bortolotti F, Resti M, Giacchino R, et al. Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. J Pediatr 1997;130:859-861
19. Resti M, Jara P, Hierro L, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 2003; 70:373-377 (Pubitemid 36638049)
20. European Pediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005;41:45-51.
21. Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol 2004;19:1357-1362
22. Deleted in proof.
23. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the PEDS-C Trial. Hepatology 2008;47:836-843
24. Rumbo C, Fawaz RL, Emre SH, et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr 2006;43:209-216
25. Murray KF, Finn LS, Taylor SL, et al. Liver histology and alanine amino transferase levels in children and adults with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2005;41:634-638
26. Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790-800.
27. Nydegger A, Srivastava A, Wake M, et al. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol 2008;23:226-230
28. Rodrigue JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009;48:341-347
29. Chesney PJ, Fisher MC, Gerber MA, et al. Hepatitis C virus infection. Pediatrics 1998;101:481-485
30. Shneider BL, González-Peralta RP, Roberts EA. Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: summary of a single-topic conference. Hepatology 2006;44:1344-1354.
31. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alf-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013-1018
32. González-Peralta RP, Deirdre KA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005;42: 1010-1018
33. Wirth S, Lang T, Gehring S, et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002;36:1280-1284
34. Christensson B, Wiebe T, Akesson A, et al. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000;30:585-586
35. Lackner H, Moser A, Deutsch J, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000;106:E53-6.
36. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002; 36(5 Suppl 1):S3-S20.
37. Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis. C J Hepatol 2007;46:395-402.
38. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterol 2005;128:343-350
39. González-Peralta RP, Langham MR, Mohan P, Colombani PM, Alford MK, Schwarz KB. Hepatocellular carcinoma in young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr; 2009;48:630-635
40. Strickland DK, Jenkins JJ, Hudson MM. Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J Pediatr Hematol Oncol 2001;23:527-529
41. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236
42. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002;36 (Suppl 1):220-225
43. Palomba E, Manzini P, Fiammengo P, et al. Natural history of perinatal hepatitis C virus infection. Clin Infect Dis 1996;23:47-50.
44. Ni YH, Chang MH, Lue HC, et al. Posttransfusion hepatitis C infection in children. Pediatrics 1994;124:709-713
45. Matsuoka S, Tatara K, Hayabuchi Y, et al. Serologic, virologic, and histologic characteristics of chronic phase hepatitis C virus disease in children infected by transfusion. Pediatrics 1994;94:919-922
46. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870
47. Sasaki N, Matsui A, Momoi M, et al. Loss of circulating hepatitis C virus in children who developed a persistent carrier state after motherto- baby transmission. Pediatr Res 1997;42:263-267
48. Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003;36:275-280
49. Iorio R, Giannattasio A, Sepe A, et al. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005;41:1431-1437
50. Bortolotti F, Jorio R, Resti M, et al. The Italian Observatory for HCV Infection and Hepatitis C in Children. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol 2007;46:783-790
51. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322
52. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998;53:1374-1381
53. Ghany MG, Strader DB, Thomas DL, et al. Diagnosiis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1337-1374
54. Tajiri H, Miyoshi Y, Funada S, et al. Prospective study of mother-toinfant transmission of hepatitis C virus. Pediatr Infect Dis J 2001; 20:10-14
55. Giacchino R, Tasso L, Timitilli A, et al. Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIVseronegative hepatitis C virus-seropositive mothers. J Pediatr 1998; 132:167-169
56. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998;132:527-530
57. Davis GL. Treatment of acute and chronic hepatitis C. Clin Liv Dis 1997;1:615-630
58. Jacobson KR, Murray K, Zellos A, et al. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002;34:52-58
59. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-1539
60. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492
61. Kelly D, Haber B, Gonzalez-Peralta RP, et al. Sustained virologic response to Interferon alpha-2b plus Ribavirin predicts long-term clearance of HCV in pediatric patients at 5 year follow-up. J Hepatol 2008;48 (Suppl 2):S298.
62. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 22:958-965
63. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982
64. Di Bisceglie AM, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepatol 2007;14:721-729
65. Schwarz KB, Mohan P, Narkewicz M, et al. The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40 kDa) in children with chronic hepatitis C. Gastroenterology 2003;124:A700.
66. Murray KF, Rodrigue JR, González-Peralta RP, et al. Design of the PEDS-C trial: pegylated interferon ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007;4:661-673
67. Schwarz KB, González-Peralta RP, Murray KF, et al. Peginterferon with or without ribavirin for chronic hepatitis C in children and adolescents: final results of the PEDS-C trial. Hepatology 2008;48:418A.
68. Wirth S, Ribes-Koninckx C, Bortolotti F, et al. Children with HCV infection show high sustained virologic response rates on peginterferon alfa-2b plus ribavirin treatment. Hepatology 2008;48:392A.
69. Jara P, Hierro L, De La Vega A, et al. Efficacy and safety of peginterferon alfa2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-148
70. Davis GL,Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652
71. Wong JB, Davis GL, McHutchison JG, et al. International Hepatitis Interventional Therapy Group. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98:2354-2362
72. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355
73. Iorio R, Pensati P, Botta S, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997;16:984-990
74. Gehring S, Kullmer U, Koeppelmann S, et al. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha.World J Gastroenterol 2006;12:5787-5792
75. Shiffmann ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa- 2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 2004;126:1015-1023
76. Jacobsen IM, Ahmed F, Russo MW, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepaitis C: a trial in nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results. Gastroenterology 2003; 124:A540.
77. Nishiguchi S, Kuroki T, Nakatami S. Randomised trail of effects of interferon on the incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055
78. Pawlowska M, Palewicz E, Halota W, et al. Early virologic response in retherapy with pegylated interferon alpha 2b plus ribavirin in children with chronic hepatitis C. Przegl Epidemiol 2006;60:71-77
79. Wanachiwanawin W, Luengrojanakul P, Sirangkapracha P, et al. Prevalence and clinical significance of hepatitis C virus infection in Thai patients with thalassemia. Int J Hematol 2003;78:374-378
80. Ansar MM, Koolobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepatol 2002;9:390-392
81. Mohan N, Majumdar I, Kaul D, et al. Prevalence of hepatitis C infection and response of treatment to interferon alpha in beta thalassemia patients. J Pediatr Gastroenterol Nutr 2004;39 (Suppl 1):S174.
82. Di Marco V, Lo Iacono O, Almasio P, et al. Long term efficacy of alphainterferon in beta-thalassemics with chronic hepatitis C. Blood 1997;90:2207-2212
83. Mohan N, GanejaV, Kaul D, et al. PEGinterferon alpha 2A (40 kDa) plus ribavirin treatment in thalassemic children and adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2007;44 (Suppl 1):e-144.
84. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, et al. Asian pacific association for the study of the liver consensus statements on the diagnosis, management and treatment of hepatitis with virus infection. J Gastroenterol Hepatol 2007;22:615-633.
85. Yamamoto K, Honda T, Matsushita T, et al. Anti-HCVagent, ribavirin, elevates the activity of clotting factor VII in patients with haemophilia: a possible mechanism of decreased events of bleeding in patients with haemophilia by ribavirin. J Thromb Haemost 2006;4:469-470
86. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Trans 2009;9:1-7.
87. Hezode C, Forestier N, Dushieko G, et al. PROVE2 study. Telaprevir with peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850
88. McHutchison JG, Everson GT, Gordon SC, et al. PROVE1 study. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838
89. Kwo P, Lawitz EJ, McCone J, et al. HCV SPRINT-1:Boceprevir puls peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. Hepatology 2008;48:268A.
90. Stoll-Keller F, Barth H, Fafi-Kremer S, et al. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 2009; 8:333-345
91. Deng Y, Zhang K, Tan W. A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice. Vaccine 2009;27:2085-2093
92. Lin Y, Kwon T, Polo J, et al. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008;82:7492-7503